24 SCHOOL ST., 2ND FLOOR, BOSTON, MA
Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
To Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Amended Management Services Agreement with Ljungaskog Consulting
CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
Q2
Q3
Notice of Late Filing for Quarterly Report
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Definitive Revised Proxy Statement